Alligator Bioscience AB Interim Report January-September 2018
STOCKHOLM, Oct. 26, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator's research and development.
Significant events July-September
-- Preclinical development of ATOR-1015 completed. Application for Clinical
Trial Authorization submitted.
-- New preclinical data supports the favorable safety profile of the 4-1BB
antibody ATOR-1017.
Events after the end of the period
-- James P. Allison and Tasuku Honjo to receive the Nobel Prize for their
pioneering work in cancer immunotherapy, directly linked to ATOR-1015.
-- Frances H. Arnold, George P. Smith and Sir Gregory P. Winter to receive
the Nobel Prize for their work on directed evolution of enzymes and
phage display, which constitutes the core in Alligator's unique FIND®
and ALLIGATOR-GOLD® technologies.
-- Alligator Bioscience received a research government grant from Vinnova.
Financial summary
July-September
-- Net sales, SEK 0.2 million (1.8).
0. Operating result, SEK -39.9 million (-24.5).
1. Result for the period, SEK -39.6 million (-25.8).
2. Result per share, SEK -0.56 (-0.36).
3. Cash and cash equivalents, incl. interest-bearing securities, SEK 478 million
(587).
4. Cash flow for the period, SEK -39.7 million (-25.4).
January-September
-- Net sales, SEK 1.4 million (5.6).
-- Operating result, SEK -123.0 million (-73.0).
-- Result for the period, SEK -119.5 million (-76.3).
-- Result per share, SEK -1.67 (-1.07).
-- Cash flow for the period, SEK -70.0 million (-141.5).
Financial summary (Group):
2018 2017 2018 2017 2017
Jul-Sep Jul-Sep Jan-Sep Jan-Sep Jan-Dec
Net sales,
TSEK (SEK
thousand) 197 1,770 1,364 5,576 56,875
Operating
profit/
loss -39,918 -24,459 -123,020 -73,032 -62,299
Profit/
loss for
the
period,
TSEK -39,635 -25,772 -119,454 -76,274 -63,758
Cash flow
for the
period,
TSEK -39,691 -25,409 -69,990 -141,479 -183,173
Cash, cash
equivalents
and bonds,
TSEK 478,355 587,578 478,355 587,578 547,041
Equity
ratio, % 95% 97% 95% 97% 96%
R&D costs
as % of
operating
costs
excluding
impairments 76.2% 69.3% 76.0% 69.5% 73.3%
Earnings
per share
before
dilution,
SEK -0.56 -0.36 -1.67 -1.07 -0.89
Earnings
per share
after
dilution,
SEK -0.56 -0.36 -1.67 -1.07 -0.89
Average
number of
employees 51 43 49 40 42
Read the complete report in the attached pdf.
For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com , +46-46-286-42-80.
Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com , +46-46-286-42-85.
Cecilia Hofvander, Director IR & Communications, cecilia.hofvander@alligatorbioscience.com , +46-46-286-44-95.
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-286-42-80.
www.alligatorbioscience.com
The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on October 26, 2018.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Main/12681/2654851/933187.pdf Alligator Bioscience AB
Interim Report January-
September 2018
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-interim-report-january-september-2018-300738530.html
SOURCE Alligator Bioscience
